Ferring Signs an Exclusive License Agreement with Invo for its INVOcell Intravaginal Culture (IVC) System in the US

 Ferring Signs an Exclusive License Agreement with Invo for its INVOcell Intravaginal Culture (IVC) System in the US

Ferring Signs an Exclusive License Agreement with Invo for its INVOcell Intravaginal Culture (IVC) System in the US

Shots:

  • Ferring to receive the US commercialization rights for INVOcell Technology and Invo will take care of its manufacturing and supplying activities for Ferring
  • Invo has rights to establish INVO clinics for exclusive commercialization of INVOcell outside the US. The agreement is expected to close in Jan, 2019
  • INVOcell is a novel technology with small polystyrene capsule, used for the treatment of infertility in women and received the US FDA approval in 2015

Click here to read full press release/ article | Ref: Invo Bioscience | Image: Florida Now

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post